Literature DB >> 4038993

Dopamine agonist activity of EMD 23,448.

G E Martin, D J Pettibone.   

Abstract

EMD 23,448 was examined in tests of dopaminergic function and was found to be an atypical dopamine (DA) agonist. EMD 23,448 was a weak or inactive DA agonist when examined in tests of normal postsynaptic DA receptor function: production of stereotypy in the rat (ED50 greater than 5.0 mg/kg i.p.); production of emesis in beagles (minimum effective dose = 81 micrograms/kg i.v.); and, enhanced locomotor activity of the mouse (no excitation in doses less than or equal to 50 mg/i.p.). Moreover, EMD 23,448 was relatively weak in competing for [3H]-apomorphine binding to rat striatal membranes (Ki, 205 nM). On the other hand, this indolyl-3-butylamine did activate supersensitive postsynaptic DA receptors. Specifically, it elicited contralateral turning in rats with a unilateral 6-hydroxydopamine lesion of the substantia nigra (ED50 value = 0.9 mg/kg) and did elicit stereotypy in rats given chronic daily haloperidol treatments. EMD 23,448 also exerted pharmacological effects in tests designed to measure activation of dopamine autoreceptors. It inhibited the gamma-butyrolactone-induced increase in striatal dopa levels (ED50 = 1 mg/kg i.p.) and produced a dose-related fall in the locomotor activity of the mouse. The results are discussed and contrasted with data derived for apomorphine and the putatively selective autoreceptor agonist (+/-)-3-PPP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038993     DOI: 10.1007/bf01253056

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  13 in total

1.  Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Mol Pharmacol       Date:  1976-09       Impact factor: 4.436

2.  Electrophysiological studies on EMD 23 448, an indolyl-3-butylamine, in the rat: a putative selective dopamine autoreceptor agonist.

Authors:  L A Chiodo; B S Bunney
Journal:  Neuropharmacology       Date:  1983-09       Impact factor: 5.250

Review 3.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

4.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.

Authors:  F Hefti; E Melamed; R J Wurtman
Journal:  Brain Res       Date:  1980-08-11       Impact factor: 3.252

5.  Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain.

Authors:  C A Seyfried; K Fuxe; H P Wolf; L F Agnati
Journal:  Acta Physiol Scand       Date:  1982-12

6.  Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug.

Authors:  P Seeman; M Chau-Wong; J Tedesco; K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

7.  Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors.

Authors:  J R Walters; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

8.  Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.

Authors:  K A Neve; C A Altar; C A Wong; J F Marshall
Journal:  Brain Res       Date:  1984-06-04       Impact factor: 3.252

9.  Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation.

Authors:  G E Martin; R J Bendesky
Journal:  J Pharmacol Exp Ther       Date:  1984-06       Impact factor: 4.030

10.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more
  3 in total

1.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

2.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

3.  Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.

Authors:  A C Barton; K E Moore; K T Demarest
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.